The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | How CAR-T will impact the future of myeloma treatment
In this video, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly comments on how CAR T-cell therapy will impact the treatment of multiple myeloma (MM) in the future. Dr Gagelmann is confident that this therapeutic option will move to the frontline setting and highlights that the newly developed MyCARe model may help predict which patients are suitable candidates for receiving CAR-T in the frontline. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
